{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:15:31Z","timestamp":1791270931777,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T00:00:00Z","timestamp":1390521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00520-014-2132-4","type":"journal-article","created":{"date-parts":[[2014,1,23]],"date-time":"2014-01-23T01:56:12Z","timestamp":1390442172000},"page":"1579-1584","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and tolerability of controlled-release oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of FOLFOX therapy in advanced colorectal cancer patients"],"prefix":"10.1007","volume":"22","author":[{"given":"Makoto","family":"Nagashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Ooshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yui","family":"Sugishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kadoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasuku","family":"Urita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Oshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Okazumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,1,24]]},"reference":[{"issue":"3 suppl","key":"2132_CR1","first-page":"S84","volume":"152","author":"JA Paice","year":"2010","unstructured":"Paice JA (2010) Chronic treatment-related pain in cancer survivors. Pain 152(3 suppl):S84\u2013S89","journal-title":"Pain"},{"key":"2132_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11916-008-0030-5","volume":"12","author":"B Malik","year":"2008","unstructured":"Malik B, Stillman M (2008) Chemotherapy-induced peripheral neuropathy. Curr Pain Headache Rep 12:165\u2013174","journal-title":"Curr Pain Headache Rep"},{"key":"2132_CR3","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1200\/JCO.2010.33.0308","volume":"29","author":"CL Loprinzi","year":"2011","unstructured":"Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, Le-Lindqwister NA, Soori GS, Jaslowski AJ, Novotny PJ, Lachance DH (2011) Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol 29:1472\u20131478","journal-title":"J Clin Oncol"},{"key":"2132_CR4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-08-0840","volume":"8","author":"SR McWhinney","year":"2009","unstructured":"McWhinney SR, Goldberg RM, McLeod HL (2009) Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther 8:10\u201316","journal-title":"Mol Cancer Ther"},{"key":"2132_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/PL00007853","volume":"249","author":"S Quasthoff","year":"2002","unstructured":"Quasthoff S, Hartung HP (2002) Chemotherapy-induced peripheral neuropathy. J Neurol 249:9\u201317","journal-title":"J Neurol"},{"key":"2132_CR6","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343\u20132351","journal-title":"N Engl J Med"},{"key":"2132_CR7","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00520-010-1018-3","volume":"19","author":"LA Kottschade","year":"2011","unstructured":"Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL (2011) The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer 19:1769\u20131777","journal-title":"Support Care Cancer"},{"key":"2132_CR8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pain.2010.10.015","volume":"152","author":"L Meyer","year":"2011","unstructured":"Meyer L, Patte-Mensah C, Taleb O, Mensah-Nyagan AG (2011) Allopregnanolone prevents and suppresses oxaliplatin-evoked painful neuropathy: multi-parametric assessment and direct evidence. Pain 152:170\u2013181","journal-title":"Pain"},{"key":"2132_CR9","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00280-010-1476-9","volume":"67","author":"MB Garg","year":"2011","unstructured":"Garg MB, Ackland SP (2011) Pyridoxine to protect from oxaliplatin-induced neurotoxicity without compromising antitumor effect. Cancer Chemother Pharmacol 67:963\u2013966","journal-title":"Cancer Chemother Pharmacol"},{"key":"2132_CR10","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1200\/JCO.2002.07.056","volume":"20","author":"RH Wilson","year":"2002","unstructured":"Wilson RH, Lehky T, Thomas RR (2002) Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 20:1767\u20131774","journal-title":"J Clin Oncol"},{"key":"2132_CR11","doi-asserted-by":"crossref","first-page":"e18469","DOI":"10.1371\/journal.pone.0018469","volume":"6","author":"SB Park","year":"2011","unstructured":"Park SB, Lin CS, Krishnan AV, Goldstein D, Friedlander ML, Kiernan MC (2011) Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity. PLoS One 6:e18469","journal-title":"PLoS One"},{"key":"2132_CR12","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV, Saif MW, Reardon J (2013) Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31:2699\u20132707","journal-title":"J Clin Oncol"},{"key":"2132_CR13","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1007\/s00520-013-1905-5","volume":"21","author":"C Tofthagen","year":"2013","unstructured":"Tofthagen C, Donovan KA, Morgan MA, Shibata D, Yeh Y (2013) Oxaliplatin-induced peripheral neuropathy\u2019s effects on health-related quality of life of colorectal cancer survivors. Support Care Cancer 21:3307\u20133313","journal-title":"Support Care Cancer"},{"key":"2132_CR14","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1007\/s00520-012-1492-x","volume":"20","author":"K Shimozuma","year":"2012","unstructured":"Shimozuma K, Ohashi Y, Takeuchi A, Aranishi T, Morita S, Kuroi K, Ohsumi S, Makino H, Katsumata N, Kuranami M, Suemasu K, Watanabe T, Hausheer FH (2012) Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC02 A randomized clinical trial. Support Care Cancer 20:3355\u20133364","journal-title":"Support Care Cancer"},{"key":"2132_CR15","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1089\/jpm.2010.0124","volume":"13","author":"C Tofthagen","year":"2010","unstructured":"Tofthagen C (2010) Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med 13:1389\u20131391","journal-title":"J Palliat Med"},{"key":"2132_CR16","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1001\/jama.293.24.3043","volume":"293","author":"E Eisenberg","year":"2005","unstructured":"Eisenberg E, McNicol ED, Carr DB (2005) Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA 293:3043\u20133052","journal-title":"JAMA"},{"key":"2132_CR17","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1503\/cmaj.051528","volume":"174","author":"AD Furlan","year":"2006","unstructured":"Furlan AD, Sandoval JA, Mailis-Gagnon A, Tunks E (2006) Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174:1589\u20131594","journal-title":"CMAJ"},{"key":"2132_CR18","doi-asserted-by":"crossref","first-page":"e59981","DOI":"10.1371\/journal.pone.0059981","volume":"8","author":"MC Garassino","year":"2013","unstructured":"Garassino MC, Piva S, La Verde N, Spagnoletti I, Iorno V, Carbone C, Febbraro A, Bianchi A, Bramati A, Moretti A, Ganzinelli M, Marabese M, Gentili M, Torri V, Farina G (2013) Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. PLoS One 8:e59981","journal-title":"PLoS One"},{"key":"2132_CR19","unstructured":"U.S. Department of Health and Human Services (2009) Common terminology criteria of adverse events (CTCAE) version 3.0"},{"key":"2132_CR20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1093\/annonc\/mds211","volume":"24","author":"F Wen","year":"2013","unstructured":"Wen F, Zhou Y, Wang W, Hu QC, Liu YT, Zhang PF, Du ZD, Dai J, Li Q (2013) Ca\/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer : a meta-analysis. Ann Oncol 24:171\u2013178","journal-title":"Ann Oncol"},{"issue":"15 suppl","key":"2132_CR21","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1200\/jco.2013.31.15_suppl.3501","volume":"31","author":"L Loprinzi","year":"2013","unstructured":"Loprinzi L, Qin R, Dakhil SR, Fehrenbacher K, Stella PJ, Atherton PJ, Seisler DK, Qamar R, Lewis GC, Grothey A (2013) Phase III randomized, placebo (PL)-controlled, double-blind study of intravenous calcium\/magnesium (CaMg) to prevent oxaliplatin-induced sensory neurotoxicity (sNT), N08CB : an alliance for clinical trials in oncology study. J Clin Oncol 31(15 suppl):3501","journal-title":"J Clin Oncol"},{"key":"2132_CR22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1590\/S1516-31802013000100006","volume":"131","author":"SO Afonseca de","year":"2013","unstructured":"de Afonseca SO, Cruz FM, de Iracema Gomes Cubero D, Lera AT, Schindler F, Okawara M, de Souza LF, Rogrigues NP, del Giglio A (2013) Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy : a pilot randomized clinical trial. Sao Paulo Med J 131:35\u201338","journal-title":"Sao Paulo Med J"},{"key":"2132_CR23","first-page":"2601","volume":"29","author":"A-L Kautio","year":"2009","unstructured":"Kautio A-L, Haanpaa M, Leminen A, Kalso E, Kautiainen H, Saarto T (2009) Amitriptyline in the prevention of chemotherapy-induced neuropathic symptoms. Anticancer Res 29:2601\u20132606","journal-title":"Anticancer Res"},{"key":"2132_CR24","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1002\/cncr.23008","volume":"110","author":"RD Rao","year":"2007","unstructured":"Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nickcevich DA, Warner DO, Novotny P, Kutteh LA, Wong GY, the North Central Cancer Treatment Group (2007) Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy : A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 110:2110\u20132118","journal-title":"Cancer"},{"key":"2132_CR25","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.1002\/cncr.23482","volume":"112","author":"RD Rao","year":"2008","unstructured":"Rao RD, Flynn PJ, Sloan JA, Wong GY, Novotny P, Johnson DB, Gross HM, Nashawaty M, Loprinzi CL (2008) Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy : A phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 112:2802\u20132808","journal-title":"Cancer"},{"key":"2132_CR26","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/annonc\/mdr045","volume":"23","author":"JP Durand","year":"2012","unstructured":"Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F (2012) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity : results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 23:200\u2013205","journal-title":"Ann Oncol"},{"key":"2132_CR27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2013.2813","volume":"309","author":"EM Smith","year":"2013","unstructured":"Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Fadul CE, Knox C, Le-Lindqwister N, Gilman PB, Shapiro CL (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309:1359\u20131367","journal-title":"JAMA"},{"key":"2132_CR28","first-page":"1091","volume":"44","author":"CE Urch","year":"2008","unstructured":"Urch CE, Dickenson AH (2008) Neuropathic pain in cancer. Eur J Pain 44:1091\u20131096","journal-title":"Eur J Pain"},{"key":"2132_CR29","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1212\/WNL.50.6.1837","volume":"50","author":"CPN Watson","year":"1998","unstructured":"Watson CPN, Babul N (1998) Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 50:1837\u20131841","journal-title":"Neurology"},{"key":"2132_CR30","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0304-3959(03)00160-X","volume":"105","author":"CP Watson","year":"2003","unstructured":"Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J (2003) Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 105:71\u201378","journal-title":"Pain"},{"key":"2132_CR31","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1212\/01.WNL.0000057720.36503.2C","volume":"60","author":"JS Gimbel","year":"2003","unstructured":"Gimbel JS, Rochards P, Portenoy RK (2003) Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 60:927\u2013934","journal-title":"Neurology"},{"key":"2132_CR32","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.ejpain.2007.12.010","volume":"12","author":"M Hanna","year":"2008","unstructured":"Hanna M, O\u2019Brien C, Wilson MC (2008) Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain 12:804\u2013813","journal-title":"Eur J Pain"},{"key":"2132_CR33","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1007\/s00520-012-1511-y","volume":"20","author":"C Cartoni","year":"2012","unstructured":"Cartoni C, Brunetti GA, Federico V, Efficace F, Grammatico S, Tendas A, Scaramucci L, Cupelli L, D\u2019Elia GM, Truini A, Niscola P, Petrucci MT (2012) Controlled-release oxycodone for the treatment of bortezomib-induced neuropathic pain in patients with multiple myeloma? Support Care Cancer 20:2621\u20132626","journal-title":"Support Care Cancer"},{"key":"2132_CR34","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.npp.1301471","volume":"33","author":"M Narita","year":"2008","unstructured":"Narita M, Nakamura A, Ozaki M, Imai S, Miyoshi K, Suzuki M, Suzuki T (2008) Comparative pharmacological profiles of morphine and oxycodone under a neuropathic pain-like state in mice: evidence for less sensitivity to morphine. Neuropsychopharmacology 33:1097\u20131112","journal-title":"Neuropsychopharmacology"},{"key":"2132_CR35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1254\/jphs.09139FP","volume":"111","author":"K Minami","year":"2009","unstructured":"Minami K, Hasegawa M, Ito H, Nakamura A, Tomii T, Matsumoto M, Orita S, Matsushima S, Miyoshi T, Masuno K, Torii M, Koike K, Shimada S, Kanemasa T, Kihara T, Narita M, Suzuki T, Kato A (2009) Morphine, oxycodone, and fentanyl exhibit different analgesic profiles in mouse pain models. J Pharmacol Sci 111:60\u201372","journal-title":"J Pharmacol Sci"},{"key":"2132_CR36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1529-8027.2011.00351.x","volume":"16","author":"B Frigeni","year":"2011","unstructured":"Frigeni B, Piatti M, Lanzani F, Alberti P, Villa P, Zanna C, Ceracchi M, Ildebrando M, Cavaaletti G (2011) Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale. J Peripher Nerv Syst 16:228\u2013236","journal-title":"J Peripher Nerv Syst"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-014-2132-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2132-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T13:34:48Z","timestamp":1597412088000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-014-2132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,24]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2132"],"URL":"https:\/\/doi.org\/10.1007\/s00520-014-2132-4","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,24]]}}}